United States National Institutes of Health grant funding for psychedelic-assisted therapy clinical trials from 2006-2020.
The International journal on drug policy January 1, 2022 Brian S Barnett, Sloane E Parker, Jeremy Weleff 57 citations
Despite a global resurgence in clinical trials of psychedelic-assisted therapies for mental health and addiction—mostly funded privately—the United States National Institutes of Health (NIH), the world's largest public biomedical funder, has not directly supported any such trial. A search of NIH grants from 2006 to 2020 for trials involving MDMA, 5-MeO-DMT, ayahuasca, DMT, ibogaine, LSD, mescaline, peyote, or psilocybin found zero grants directly funding psychedelic-assisted therapy clinical trials. Possible reasons include concerns about risks, a federal law barring promotion of Schedule 1 drug legalization, and prioritization of other psychedelic research.